Selecta Biosciences (SELB) Misses Q1 EPS by 10c, Revenues Beat

Selecta Biosciences (NASDAQ: SELB) reported Q1 EPS of ($0.22), $0.10 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $11.05 million versus the consensus estimate of $7.52 million.

“We are very pleased about the continued progress across all aspects of the company,” said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. “We regained exclusive rights to our MMA program and now have two proprietary gene therapy programs to rapidly follow our ongoing empty capsid study. Additionally, we continue to progress our enzyme program, with an expected IND filing by the end of 2021 in IgA nephropathy, and topline data from the Phase 3 DISSOLVE program for SEL-212 anticipated in the second half of 2022.”

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• Optimum Communications gets NYSE non-compliance notice over stock price